Exsure, a pioneering biotech startup, has raised ₹3 crore in a seed funding round led by Unicorn India Ventures. The funding will expedite the completion of non-clinical studies for Exsure’s patented exosome-based drug delivery technology, aimed at minimizing the side effects and toxicity of chemotherapy. Additionally, the funds will support global expansion and the development of its innovative R&D products, including Exosure, Leucosure, PlantExosure, and Dr. Berries.
Transforming Cancer Therapy with Exosomes
Founded in 2021 by Swastika Paul and Abhishek Dutta, Exsure is on a mission to revolutionize cancer therapy by improving survival rates and the quality of life for patients. The company’s patented platform leverages exosome-based drug delivery to reduce chemotherapy toxicity, ensuring targeted and effective treatment of cancer and stem cells.
Key achievements include:
- A 5-fold revenue increase in the last fiscal year.
- Launching India’s first plant exosome isolation reagent, further establishing its position as a leader in the biotech industry.
Industry Backing and Market Potential
Bhaskar Majumdar, from Unicorn India Ventures, emphasized Exsure’s potential to transform cancer treatment:
“Exsure’s innovative technology addresses a critical need in the market by reducing chemotherapy toxicity while improving outcomes for patients. The global demand for such solutions highlights the vast opportunities ahead.”
Global Expansion and R&D Focus
Exsure’s strategic use of funding will drive its upcoming milestones, including:
- Advancing non-clinical studies for its exosome-based platform.
- Expanding the reach of its in-house manufactured R&D products, including Exosure for exosome isolation and Leucosure for stem cell therapy.
- Scaling globally to position itself as a frontrunner in cancer treatment innovation.
Future Vision: Improving Lives with Cutting-Edge Solutions
Exsure’s revolutionary approach to cancer therapy not only enhances treatment outcomes but also promises a better quality of life for patients. With its focus on research and global scalability, the company is well on its way to redefining cancer treatment worldwide.